Global Autoinjectors Strategic Market Report 2023: Market to Reach $168.2 Billion by 2030

Global market for autoinjectors

Dublin, Feb. 01, 2023 (GLOBE NEWSWIRE) — The “Autoinjectors – Global Strategic Business Report” report has been added to ResearchAndMarkets.com offer.

The global auto-injector market will reach $168.2 billion by 2030

In the changed business environment after the COVID-19 pandemic, the global auto-injectors market, which is estimated at USD 50.9 billion in 2022, is projected to reach a revised size of USD 168.2 billion by 2030, growing at a CAGR during the analysis period 16.1%. 2022-2030.

Rheumatoid arthritis, one of the segments analyzed in the report, is projected to register a CAGR of 16% to reach USD 47.6 billion by the end of the analysis period. Taking into account the ongoing recovery from the pandemic, growth in the anaphylaxis segment is adjusted to a revised 15.9% CAGR for the next 8-year period.

The US market is estimated at $13.9 billion, while China is forecast to grow at a CAGR of 21.4%

The US auto-injector market is estimated to reach $13.9 billion by 2022. China, the world’s second largest economy, is forecast to reach a projected market size of USD 40.4 billion by 2030, a CAGR of 21.4% over analysis. period 2022 to 2030.

Other notable geographic markets include Japan and Canada, each forecast to grow by 11.9% and 13.8% over the period 2022-2030. Within Europe, Germany is projected to grow at around 12.8% CAGR. Led by countries such as Australia, India and South Korea, the Asia Pacific market is expected to reach $26.4 billion by 2030.

Looking to 2023

Concerns about a new outbreak of COVID and China’s already uncertain post-pandemic path pose a real risk that the world will experience more acute supply chain pain and manufacturing disruptions this year.

2023 is expected to be a challenging year for most markets, investors and consumers. Yet there is always opportunity for businesses and their leaders to forge a path forward with resilience and adaptability.

What’s new for 2023?

The story continues

• Special coverage of the Russian-Ukrainian war; global inflation; the relaxation of China’s zero-Covid policy and its “bumpy” reopening; supply chain disruptions, global trade tensions; and the risk of recession.

• Global competitiveness and percentage shares of the key competitor in the market

• Market presence in multiple geographies – strong/active/niche/trivial

• Online, interactive, tailored updates based on peer-to-peer collaboration

• Access to digital archives and research platform

• Free updates for one year

Key metrics

Key topics:

MARKET OVERVIEW

• Influencer Market Insights

• Trajectories of the world market

• The rapid transition from self-injectors to auto-injectors for easy and safe medication administration is driving demand

• North America: Largest market for auto-injectors

• Autoinjectors – Global Key Competitors Market Share in 2022 (E)

• Global Epinephrine Autoinjectors Market: Volume Sales Percentage Breakdown by Leading Players 2019E

• The impact of Covid-19 and the looming global recession

• Competitive Market Presence – Strong/Active/Niche/Trivial for Global Players in 2022 (E)

FOCUS ON SELECTED PLAYERS (Total 42 recommended)

• AbbVie, Inc.

• Amgen, Inc.

• Antares Pharma, Inc.

• Becton, Dickinson and Company

• Consort Medical PLC

• Eli Lilly and Company

• Haselmeier GmbH

• Mylan NV

• Owen Mumford Ltd.

• SHL Group

• Teva Pharmaceutical Industries Ltd.

• Ypsomed AG

TRENDS AND DRIVER

• Growing prevalence of targeted therapies such as cancer, rheumatoid arthritis, multiple sclerosis and diabetes: a strong driver

• Number of new cancer cases in the world in 2012, 2015, 2020, 2025 and 2030

• Prevalence of diabetes in the age group 20-79 years in millions by region in 2018, 2021 and 2025

• Global Injectable Drug Delivery Market: Revenue in Billion USD 2016, 2018, 2020, 2022 and 2024

• Rising incidence of anaphylaxis and increased prescription rate of epinephrine auto-injectors is driving market demand

• Increasing number of regulatory approvals for auto-injectors for various diseases

• Generic auto-injectors are taking center stage

• Patent expiration of biologics to increase demand for biosimilars

• Strong government support and favorable reimbursement policies are driving the market growth

• Challenges

• Development of autoinjectors for multiple drug viscosities: a major challenge

• Growing demand for alternative drug delivery regimens is hampering market growth

• Emergence of oral diabetics, oral insulin and epinephrine nasal sprays pose a huge challenge to the autoinjector market

• Product overview

• Autoinjector: Definition

For more information on this report, visit https://www.researchandmarkets.com/r/7255oo

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

Side dish

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900